Stuart Lutzker - 02 Feb 2026 Form 4 Insider Report for ArriVent BioPharma, Inc. (AVBP)

Role: President of R&D, Director
Signature: /s/ James Kastenmayer, Attorney-in-Fact for Stuart Lutzker
Issuer symbol: AVBP
Transactions as of: 02 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Feb 2026, 20:43:08 UTC
Previous filing: 14 Feb 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Lutzker Stuart	President of R&D, Director	C/O ARRIVENT BIOPHARMA, INC., 18 CAMPUS BOULEVARD, SUITE 100, NEWTOWN SQUARE	/s/ James Kastenmayer, Attorney-in-Fact for Stuart Lutzker	04 Feb 2026	0002009257

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVBP	Stock Option (right to buy)	Award	$0	+150,000		$0.000000	150,000	02 Feb 2026	Common Stock	150,000	$22.67	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.